# Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Study · id `cardio:ct-nct06643819` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06643819](<https://clinicaltrials.gov/study/NCT06643819>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06643819

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.

## Technical summary

Registry record NCT06643819. Randomized; double masking; primary purpose treatment. Start 2024-10-14 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 324 participants (planned count; ClinicalTrials.gov record NCT06643819, source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)
- Started: 2024-10-14 (actual) (ClinicalTrials.gov record NCT06643819, source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)
- Primary completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT06643819, source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06643819, source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06643819, source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06643819-2025-12-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- Condition: Essential Hypertension
- Intervention (Drug): Sacubitril∙Valsartan(dose maintenance)
- Intervention (Drug): Sacubitril∙Valsartan(dose increasing)
- Intervention (Drug): Valsartan
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: f94d59fba9602821e51d327198cf99a1211bfd960fdc915df2d33d7abef636ad
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
